Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18056186rdf:typepubmed:Citationlld:pubmed
pubmed-article:18056186lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:18056186lifeskim:mentionsumls-concept:C0023474lld:lifeskim
pubmed-article:18056186lifeskim:mentionsumls-concept:C0035696lld:lifeskim
pubmed-article:18056186lifeskim:mentionsumls-concept:C0312418lld:lifeskim
pubmed-article:18056186lifeskim:mentionsumls-concept:C0441889lld:lifeskim
pubmed-article:18056186lifeskim:mentionsumls-concept:C0243161lld:lifeskim
pubmed-article:18056186lifeskim:mentionsumls-concept:C0935989lld:lifeskim
pubmed-article:18056186lifeskim:mentionsumls-concept:C1977882lld:lifeskim
pubmed-article:18056186lifeskim:mentionsumls-concept:C0205360lld:lifeskim
pubmed-article:18056186lifeskim:mentionsumls-concept:C0549178lld:lifeskim
pubmed-article:18056186lifeskim:mentionsumls-concept:C1522326lld:lifeskim
pubmed-article:18056186lifeskim:mentionsumls-concept:C0036667lld:lifeskim
pubmed-article:18056186lifeskim:mentionsumls-concept:C0332232lld:lifeskim
pubmed-article:18056186lifeskim:mentionsumls-concept:C0439234lld:lifeskim
pubmed-article:18056186lifeskim:mentionsumls-concept:C2825407lld:lifeskim
pubmed-article:18056186lifeskim:mentionsumls-concept:C0332293lld:lifeskim
pubmed-article:18056186pubmed:issue23lld:pubmed
pubmed-article:18056186pubmed:dateCreated2007-12-6lld:pubmed
pubmed-article:18056186pubmed:abstractTextIn the first years of imatinib treatment, BCR-ABL remained detectable in all but a small minority of patients with chronic myeloid leukemia. We determined whether BCR-ABL continues to decline with longer imatinib exposure and the incidence and consequence of undetectable BCR-ABL.lld:pubmed
pubmed-article:18056186pubmed:languageenglld:pubmed
pubmed-article:18056186pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18056186pubmed:citationSubsetIMlld:pubmed
pubmed-article:18056186pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18056186pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18056186pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18056186pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18056186pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18056186pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18056186pubmed:statusMEDLINElld:pubmed
pubmed-article:18056186pubmed:monthDeclld:pubmed
pubmed-article:18056186pubmed:issn1078-0432lld:pubmed
pubmed-article:18056186pubmed:authorpubmed-author:HughesTimothy...lld:pubmed
pubmed-article:18056186pubmed:authorpubmed-author:GriggAndrewAlld:pubmed
pubmed-article:18056186pubmed:authorpubmed-author:SeymourJohn...lld:pubmed
pubmed-article:18056186pubmed:authorpubmed-author:BranfordSusan...lld:pubmed
pubmed-article:18056186pubmed:authorpubmed-author:RudzkiZbignie...lld:pubmed
pubmed-article:18056186pubmed:authorpubmed-author:ArthurChrisClld:pubmed
pubmed-article:18056186pubmed:authorpubmed-author:LynchKevinKlld:pubmed
pubmed-article:18056186pubmed:issnTypePrintlld:pubmed
pubmed-article:18056186pubmed:day1lld:pubmed
pubmed-article:18056186pubmed:volume13lld:pubmed
pubmed-article:18056186pubmed:ownerNLMlld:pubmed
pubmed-article:18056186pubmed:authorsCompleteYlld:pubmed
pubmed-article:18056186pubmed:pagination7080-5lld:pubmed
pubmed-article:18056186pubmed:meshHeadingpubmed-meshheading:18056186...lld:pubmed
pubmed-article:18056186pubmed:meshHeadingpubmed-meshheading:18056186...lld:pubmed
pubmed-article:18056186pubmed:meshHeadingpubmed-meshheading:18056186...lld:pubmed
pubmed-article:18056186pubmed:meshHeadingpubmed-meshheading:18056186...lld:pubmed
pubmed-article:18056186pubmed:meshHeadingpubmed-meshheading:18056186...lld:pubmed
pubmed-article:18056186pubmed:meshHeadingpubmed-meshheading:18056186...lld:pubmed
pubmed-article:18056186pubmed:meshHeadingpubmed-meshheading:18056186...lld:pubmed
pubmed-article:18056186pubmed:meshHeadingpubmed-meshheading:18056186...lld:pubmed
pubmed-article:18056186pubmed:meshHeadingpubmed-meshheading:18056186...lld:pubmed
pubmed-article:18056186pubmed:meshHeadingpubmed-meshheading:18056186...lld:pubmed
pubmed-article:18056186pubmed:meshHeadingpubmed-meshheading:18056186...lld:pubmed
pubmed-article:18056186pubmed:meshHeadingpubmed-meshheading:18056186...lld:pubmed
pubmed-article:18056186pubmed:meshHeadingpubmed-meshheading:18056186...lld:pubmed
pubmed-article:18056186pubmed:year2007lld:pubmed
pubmed-article:18056186pubmed:articleTitleBCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.lld:pubmed
pubmed-article:18056186pubmed:affiliationInstitute of Medical and Veterinary Science, Adelaide, Australia. susan.branford@imvs.sa.gov.aulld:pubmed
pubmed-article:18056186pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18056186pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:18056186pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18056186lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18056186lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18056186lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18056186lld:pubmed